Advocacy intelligence hub — real-time data for patient organizations
West China Hospital — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Sovaldi
(sofosbuvir)Orphan drugstandardGilead Sciences, Inc.
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
12.1 Mechanism of Action Sofosbuvir is a direct-acting antiviral agent against the hepatitis C virus [see Microbiology (12.4) ].
Epclusa
(sofosbuvir and velpatasvir)Orphan drugstandardGilead Sciences, Inc.
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
12.1 Mechanism of Action EPCLUSA is a fixed-dose combination of sofosbuvir and velpatasvir, which are direct-acting antiviral agents against the hepat...
Browse all Chronic Epstein-Barr virus infection syndrome news →
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Paolo Caimi, MD, M.D
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
📍 CLEVELAND, OH
Colleen Delaney, MD
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 OLD GREENWICH, CT
Susan K. Parsons, MD, MRP
Tufts Medical Center Cancer Center
Paul Martin
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Karen Syrjala
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
View all Chronic Epstein-Barr virus infection syndrome specialists →